Abstract
Few mutations have been described in BRCA1 and BRCA2 in high-risk non-Ashkenazi Jews. In a Libyan family the 1100delAT BRCA1 mutation was detected and the 8765delAG BRCA2 mutation was previously described in two Jewish-Yemenite-families. In this study, the rate of these mutations in high-risk Jews of North African and Yemenite origin was assessed, and the BRCA1-linked haplotype of Jewish and non-Jewish 1100delAT mutation carriers were compared. Genotyping included 64 high-risk Yemenite women (tested only for the BRCA2 mutation) and 147 high-risk North African women, tested for both mutations. PCR amplification was followed by either restriction enzyme digestion or DGGE or dHPLC analyses and direct sequencing. For haplotyping, 5 BRCA1-linked markers were used. Neither the 1100delAT BRCA1 nor the 8765delAG BRCA2 mutations were detected in any non-Ashkenazi individual. The haplotype of the non-Jewish 1100delAG mutation carrier differed from that of the Jewish-Libyan mutation carriers. We conclude that both 1100delAT BRCA1 and 8765delAG BRCA2 mutations occur rarely in high-risk non-Ashkenazi Jews, and while the latter seems to be a founder mutation in some populations, the former occurs on a different background in ethnically diverse families.
Original language | English |
---|---|
Pages (from-to) | 11-14 |
Number of pages | 4 |
Journal | Familial Cancer |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - 2004 |
Externally published | Yes |
Bibliographical note
Funding Information:This study was performed in part in fulfillment of the requirements of Inbar Gal towards her masters degree at the Department of Human Genetics, Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel. This study was sponsored in part by a grant from the Middle East Cancer Consortium (MECC) to Eitan Friedman.
Funding
This study was performed in part in fulfillment of the requirements of Inbar Gal towards her masters degree at the Department of Human Genetics, Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel. This study was sponsored in part by a grant from the Middle East Cancer Consortium (MECC) to Eitan Friedman.
Funders | Funder number |
---|---|
Middle East Cancer Consortium |
Keywords
- BRCA1/2
- Founder mutations
- Genetic isolate
- High-risk non-Ashkenazim
- Shared haplotype